lenalidomide has been researched along with succinimide in 2 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (succinimide) | Trials (succinimide) | Recent Studies (post-2010) (succinimide) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 178 | 0 | 84 |
| Protein | Taxonomy | lenalidomide (IC50) | succinimide (IC50) |
|---|---|---|---|
| Cereblon isoform 4 | Magnetospirillum gryphiswaldense | 5.565 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bär, K; Giannis, A; Hartmann, MD; Heim, C; Hernandez Alvarez, B; Mousavizadeh, F; Pliatsika, D | 1 |
| Hartmann, MD; Heim, C; Hernandez Alvarez, B; Maiwald, S | 1 |
2 other study(ies) available for lenalidomide and succinimide
| Article | Year |
|---|---|
De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.
Topics: Adaptor Proteins, Signal Transducing; Cell Line; Drug Design; Humans; Hydrolysis; Ikaros Transcription Factor; Molecular Docking Simulation; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2019 |
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
Topics: | 2021 |